A Renewed Era of Federal-Tribal Relations

whitePaper | March 16, 2023

Public agencies experience unique challenges that aren’t found in the private sector. Agencies have to comply with constitutional requirements, and usually do so on tighter budgets and with limited staff members. Our whitepaper explores the biggest challenges government teams are facing with eDiscovery.

whitePaper | January 22, 2020

Trade in “services” refers to a wide and growing range of economic activities. These activities include transport, tourism, financial services, use of intellectual property, telecommunications and information services, government services, maintenance, and other professional services from accounting to legal services. Compared to goods, the types and volume of services that can be traded are limited by factors such as the requirement for direct buyer-provider contact, and other unique characteristics such as the reusability of services (e.g., professional consulting) for which traditional value measures do not account. In addition to services as independent exports, manufactured and agricultural products incorporate and depend on services, such as research and development or shipping of intermediate or final goods. As services account for 71% of U.S. employment, U.S. trade in services, both services as exports and as inputs to other exported products, can have a broad impact across the U.S. economy.

whitePaper | January 29, 2020

Individual government contractors face more rigorous scrutiny, as private companies can monitor employee’s social media as part of their continuous vetting and insider threat protocols. However, despite the existence of a directive permitting them to do so, government agencies do not monitor their employees’ social media. Our interviews found this is due to a lack of clear guidance on how to implement the existing directives and security policies. This shortcoming can be remedied by government agencies agreeing upon a single common standard regarding the use of publicly available electronic information, specifically social media, for personnel security and insider threat purposes. The DNI, as Security Executive Agent for the government, must then develop guidelines for the implementation of this standard throughout the sector.

whitePaper | March 14, 2022

Appian Government Cloud (AGC) is a cloud service offering with a DISA Provisional Authorization (PA) at Impact Level 5 (IL5). US Department of Defense Mission Owners can leverage the AGC PA to reduce their security responsibilities and accelerate their Authority to Operate (ATO) for cloud applications. Applications deployed on AGC are built using the Appian Low-Code Platform

whitePaper | April 30, 2022

Sovereign Wealth Funds (SWFs) remain a prominent and diverse group of global asset owners. They represent unencumbered fiscal resources of the host governments, invested under a range of different mandates. In this study, we considered 34 of the largest SWFs, located in 26 different jurisdictions, which as of year-end 2020, have total assets of almost $8.5 trillion, representing 5% of total global markets.2 Between 2018 and 2020, total SWF assets under management (AUM) grew by an annualized 11.3%, as compared to 5.5% over the previous time period (Figure 1). We find that the acceleration in AUM growth is largely a function of market gains due to the post-2018 drawdown in equities. However, we estimate that organic inflows into global SWF holdings are roughly in line with the mid-single digits during the 2014–2018 time period.

whitePaper | December 10, 2019

The Trump administration, members of Congress from both parties, and many states have introduced proposals to combat high drug prices. Too often missing from these reform efforts, however, is a clear understanding of a root cause of the crisis: the suppression of fair market competition through various forms of monopoly. This white paper examines and proposes solutions for the two main ways that monopoly drives up the costs and lowers the quality of prescription drugs: increasing corporate concentration in the pharmaceutical industry, and the monopoly markets for individual drugs created by a deeply flawed and increasingly abused patent and regulatory system.